Sutro Biopharma Inc Dossier
Qualitative Analysis
Business overview
Sutro Biopharma, Inc. is a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs). The company leverages its proprietary cell-free protein synthesis platform, XpressCF, and site-specific conjugation platform, XpressCF+, to design precision therapeutics for cancer and autoimmune diseases. Sutro's platform is engineered to fully optimize the antibody, linker, and payload, producing single- and dual-payload ADCs designed to improve drug exposure, reduce side effects, and overcome treatment resistance.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Sutro implemented a major organizational restructuring to prioritize the advancement of its three key ADC programs (STRO-004, STRO-006, and STRO-227) and research collaborations. This included a workforce reduction of approximately one-third of employees and the deprioritization of luveltamab tazevibulin (luvelta) development.
Expected impact: Extends the company's cash runway, optimizes operational efficiencies, and focuses resources on high-potential next-generation ADC assets.
Sutro fully externalized its cell-free manufacturing capabilities to scale up production externally, leading to the planned cessation of internal GMP manufacturing operations at its San Carlos facility.
Expected impact: Reduces fixed overhead costs and leverages external CDMO expertise to support clinical-stage pipeline scale-up.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Focuses on the development of dual-payload immunostimulatory ADCs (iADCs). The first program targeting TROP2 entered clinical development in early 2026, and the second program entered IND-enabling toxicology studies in late 2025.
Terms: Sutro received a $90 million upfront payment in 2022 and is eligible for up to $422.5 million in development, regulatory, and commercial milestones per candidate, plus tiered royalties. A $10 million milestone was triggered in Q1 2026 for the first program entering the clinic, and a $7.5 million milestone was triggered for the second program.